Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Coroventis is a privately held Swedish cardiovascular medical technology company based in Uppsala that develops diagnostic tools for interventional cardiology. Its core commercial product is the CoroFlow Cardiovascular System, a software- and device-based platform used in the cath lab to assess both epicardial coronary disease and coronary microvascular dysfunction using physiology measurements such as fractional flow reserve, resting full-cycle ratio, coronary flow reserve, index of microvascular resistance, absolute flow, and resistance metrics. The company positions itself around innovative cardiovascular research tools and product/market development, with a particular focus on bringing advanced coronary physiology and microcirculation assessment into routine clinical practice. Abbott serves as the worldwide distributor for Coroventis products, and CoroFlow is designed to work with Abbott's PressureWire X and related hardware. Coroventis appears to operate as a small private medtech company rather than a therapeutics developer, so it does not have a traditional drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Coroventis.